Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daunorubicin Dose-Intensification in AML
NCT00049517Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Dec 2002
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of daunorubicin, gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Eastern Cooperative Oncology Group. Started Dec 2002; status: completed.
02
Drugs
daunorubicingemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00049517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049517.